Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsDowngradesPrice Target
Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE:EVH) from Buy to Hold and maintains the price target from $7 to $7.
Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE:EVH) from Buy to Hold and maintains the price target from $7 to $7.